INTERNATIONAL CONGRESS OF
CancerGenetics
Assessing the Potential of CERS6-AS1 Long Non-Coding RNA as a Biomarker for Distinguishing Normal Tissue from Tumor Tissue in Transitional Cell Carcinoma Patients: An Exploratory Study
-
Helia Azodian Ghajar,1,*
1. Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
- Introduction: Objective: In the present study, we aimed to elucidate the role of lncRNA CERS6-AS1 in BC patients to discriminate between tumor tissue and healthy counterparts. Method: This study was conducted on 40 bladder tumor tissues and normal tissue adjacent as a control sample. Initially, we extracted RNA from all samples and used them for cDNA synthesis. Employing the real-time PCR technique, we assessed expression levels of lncRNA CERS6-AS1 in both sample groups. Statistical studies were performed by graphpad prism. The relationship between lncRNA CERS6-AS1 expression levels was examined in relation to variables such as age, gender, smoking history, tumor stage, and tumor grade. Results: We discerned that expression of lncRNA CERS6-AS1 was notably elevated in tumorous tissue compared to healthy counterparts (P-value< 0.001). There was no statistically significant difference between tumor and control samples in terms of gender and age. Moreover, the expression of lncRNA CERS6-AS1 was not correlated with smoking rate, tumor grade, stage, and tumor size. Conclusion: The findings suggest that lncRNA CERS6-AS1 levels may potentially serve as a risk factor for bladder cancer susceptibility. To substantiate our findings, it is necessary to conduct further investigations with expanded sample cohorts and diverse ethnic backgrounds.
- Methods: In our study, in the first step, we analyzed the expression pattern of our interest lncRNA, CERS6-AS1, in The Cancer Genome Atlas (TCGA)-Bladder Urothelial Carcinoma (BLCA). To show consistency in the CERS6-AS1 expression in TCGA-BLCA, we investigated its expression in this database using different web tools GEPIA2 (http://gepia2.cancer-pku.cn/) (2), and TNMPLOT (https://tnmplot.com/analysis/) (3) To proceed with molecular analysis, all tissue samples were securely stored in cryovial containers at a low temperature of -80°C. This preservation method helps preserve the samples' integrity and quality for further examination. The QIAGEN real-time PCR device and Rotor-Gene Q were utilized to evaluate the CERS6-AS1 lncRNA expression levels
- Results: We discerned that expression of lncRNA CERS6-AS1 was notably elevated in tumorous tissue compared to healthy counterparts (P-value< 0.001). There was no statistically significant difference between tumor and control samples in terms of gender and age. Moreover, the expression of lncRNA CERS6-AS1 was not correlated with smoking rate, tumor grade, stage, and tumor size.
- Conclusion: In summary, the findings of the study propose that CERS6-AS1 is overexpressed in bladder cancer (BC) tissues. However, it was observed that the expression levels of CERS6-AS1 were not significantly associated with tumor grade and stage, pathological tumor size, age, gender, or smoking status. These results indicate that CERS6-AS1 may play a role in bladder cancer progression, but its relationship with other clinical factors remains inconclusive. More research is required to explore the exact mechanisms underlying the function of CERS6-AS1 in BC and to determine its potential as a prognostic or therapeutic target.
- Keywords: Bladder cancer; Long non-coding RNAs, CERS6-AS1
